{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:46:45Z","timestamp":1789685205195,"version":"4.0.1"},"reference-count":235,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000395","name":"Royal College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-026-00707-6","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:46:19Z","timestamp":1775094379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-5734","authenticated-orcid":false,"given":"Christo","family":"Albor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-2299","authenticated-orcid":false,"given":"Oluwaseun","family":"Anyiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-9170","authenticated-orcid":false,"given":"Luke D.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Makaronidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-6810","authenticated-orcid":false,"given":"Rachael","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1099-820X","authenticated-orcid":false,"given":"Amna","family":"Burzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fannie","family":"Lajeunesse Trempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7778-2272","authenticated-orcid":false,"given":"Aniqah","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-712X","authenticated-orcid":false,"given":"Jadine","family":"Scragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-9404","authenticated-orcid":false,"given":"Layla","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Moqeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7548-8288","authenticated-orcid":false,"given":"Iskandar","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-1738","authenticated-orcid":false,"given":"Rob C.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2800-7365","authenticated-orcid":false,"given":"Piya","family":"Sen Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"707_CR1","unstructured":"NICE. Semaglutide for managing overweight and obesity [Internet]. 2023 [cited 2025 Oct 1]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta875. Accessed 22 Oct 2025."},{"key":"707_CR2","doi-asserted-by":"crossref","unstructured":"Boyle L, Albor C, Anyiam O, Gupta PS, Coelho C, Crane J, et al. Guidance for the phased introduction of new medical therapies for weight management: A joint position statement by the Society for Endocrinology and Obesity Management Collaborative UK [Internet]. 2023. Available from: https:\/\/www.endocrinology.org\/media\/sjdpporx\/joint-position-statement-on-medical-therapies-for-obesity_final-resubmitted-sfe-211223.pdf. Accessed 22 Oct 2025.","DOI":"10.1530\/obabs.4.P3"},{"key":"707_CR3","unstructured":"NICE. Tirzepatide for managing overweight and obesity [Internet]. 2024 [cited 2025 Oct 1]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1026. Accessed 22 Oct 2025."},{"key":"707_CR4","unstructured":"NHS-England. Interim commissioning guidance: Implementation of the NICE Technology Appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro\u00ae) for the management of obesity. [Internet]. 2025 [cited 2025 Oct 1]. Available from: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2025\/03\/PRN01879-interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-NICE-fu.pdf. Accessed 22 Oct 2025."},{"key":"707_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Gaal LV, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399\u2013409.","journal-title":"Lancet"},{"key":"707_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687\u201399.","journal-title":"JAMA"},{"key":"707_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes. 2013;37:1443\u201351.","journal-title":"Int J Obes"},{"key":"707_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LFV, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"707_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971\u201384.","journal-title":"Lancet"},{"key":"707_CR10","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA. 2021;325:1414\u201325.","journal-title":"JAMA"},{"key":"707_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391.","journal-title":"Nat Med"},{"key":"707_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA. 2022;327:138\u201350.","journal-title":"JAMA"},{"key":"707_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M, Pedersen SD, Pietil\u00e4inen KH, Muniraju HAK, et al. Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12:631\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"707_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, M\u00f8ller DV, Shah SJ. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384. https:\/\/doi.org\/10.1056\/nejmoa2306963","journal-title":"N Engl J Med"},{"key":"707_CR15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394\u2013407.","journal-title":"N Engl J Med"},{"key":"707_CR16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332.","journal-title":"N Engl J Med"},{"key":"707_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"707_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109\u201321.","journal-title":"N Engl J Med"},{"key":"707_CR19","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089\u201399.","journal-title":"N Engl J Med"},{"key":"707_CR20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2024","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2024;392:958\u201371.","journal-title":"N Engl J Med"},{"key":"707_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin W-Y, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA. 2024;331:38\u201348.","journal-title":"JAMA"},{"issue":"13","key":"707_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"key":"707_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392:427\u201337.","journal-title":"N Engl J Med"},{"key":"707_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393\u2013403.","journal-title":"N Engl J Med"},{"key":"707_CR25","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.2337\/dc06-0560","volume":"29","author":"RF Hamman","year":"2006","unstructured":"Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102\u20137.","journal-title":"Diabetes Care"},{"key":"707_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541\u201351.","journal-title":"Lancet"},{"key":"707_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Land\u00f3 LF, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143\u201355.","journal-title":"Lancet"},{"key":"707_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Land\u00f3 LF, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583\u201398. Accessed 22 Oct 2025.","journal-title":"Lancet"},{"key":"707_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, Manghi FCP, Land\u00f3 LF, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"707_CR30","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang C-Z, Wan J-Y, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.","journal-title":"BMJ"},{"key":"707_CR31","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.eclinm.2023.102181","volume":"64","author":"I Caruso","year":"2023","unstructured":"Caruso I, Gioia LD, Molfetta SD, Cignarelli A, Palmer SC, Natale P, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. eClinicalMedicine. 2023;64:102181.","journal-title":"eClinicalMedicine."},{"key":"707_CR32","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Prato SD, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"707_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/SA.0b013e3182752111","volume":"56","author":"L Sj\u00f6str\u00f6m","year":"2012","unstructured":"Sj\u00f6str\u00f6m L, Peltonen M, Jacobson P, Sj\u00f6str\u00f6m CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. Surv Anesthesiol. 2012;56:327\u20138.","journal-title":"Surv Anesthesiol"},{"key":"707_CR34","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2019.14231","volume":"322","author":"A Aminian","year":"2019","unstructured":"Aminian A, Zajichek A, Arterburn DE, Wolski KE, Brethauer SA, Schauer PR, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322:1271\u201382.","journal-title":"JAMA"},{"key":"707_CR35","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1161\/CIRCULATIONAHA.120.052386","volume":"143","author":"A Doumouras","year":"2021","unstructured":"Doumouras A, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride J-\u00c9, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study. Circulation. 2021;143:1468\u201380.","journal-title":"Circulation"},{"key":"707_CR36","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1093\/eurheartj\/ehaa069","volume":"41","author":"O Moussa","year":"2020","unstructured":"Moussa O, Ardissino M, Heaton T, Tang A, Khan O, Ziprin P, et al. Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. Eur Heart J. 2020;41:2660\u20137.","journal-title":"Eur Heart J"},{"key":"707_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/bjs.11433","volume":"107","author":"P Singh","year":"2020","unstructured":"Singh P, Subramanian A, Adderley N, Gokhale K, Singhal R, Bellary S, et al. Impact of bariatric surgery on cardiovascular outcomes and mortality: a population-based cohort study. Br J Surg. 2020;107:432\u201342.","journal-title":"Br J Surg"},{"key":"707_CR38","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519\u201329.","journal-title":"Lancet"},{"key":"707_CR39","doi-asserted-by":"publisher","first-page":"q1660","DOI":"10.1136\/bmj.q1660","volume":"386","author":"G Iacobucci","year":"2024","unstructured":"Iacobucci G. Semaglutide: UK regulator approves drug for prevention of cardiovascular events. BMJ. 2024;386:q1660.","journal-title":"BMJ"},{"key":"707_CR40","unstructured":"Lilly. Lilly\u2019s Mounjaro (tirzepatide), a GIP\/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease [Internet]. 2025 [cited 2025 Oct 23]. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated"},{"key":"707_CR41","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/ejhf.3270","volume":"26","author":"KH Peck","year":"2024","unstructured":"Peck KH, Dulay MS, Hameed S, Rosano G, Tan T, Dar O. Intentional weight loss in overweight and obese patients with heart failure: a systematic review. Eur J Heart Fail. 2024;26:1907\u201330.","journal-title":"Eur J Heart Fail"},{"key":"707_CR42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404:949\u201361.","journal-title":"Lancet"},{"key":"707_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2023.102355","volume":"69","author":"JC Ribeiro-Silva","year":"2023","unstructured":"Ribeiro-Silva JC, Tavares CAM, Girardi ACC. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms. Curr Opin Pharmacol. 2023;69:102355.","journal-title":"Curr Opin Pharmacol"},{"key":"707_CR44","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes, Obes Metab. 2013;15:737\u201349.","journal-title":"Diabetes, Obes Metab"},{"key":"707_CR45","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","volume":"25","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, Obes Metab. 2023;25:468\u201378. Accessed 22 Oct 2025.","journal-title":"Diabetes, Obes Metab"},{"key":"707_CR46","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.hrthm.2023.04.029","volume":"20","author":"JJ Goldberger","year":"2023","unstructured":"Goldberger JJ, Mitrani RD, Baez-Garcia C, Blandon C, Zaatari G, Velasquez AH, et al. LB-456089-1 pre-ablation weight loss as a predictor of atrial fibrillation ablation outcome in the liraglutide effect on atrial fibrillation (leaf) study. Hear Rhythm. 2023;20:1079.","journal-title":"Hear Rhythm"},{"key":"707_CR47","doi-asserted-by":"publisher","first-page":"103067","DOI":"10.1016\/j.dsx.2024.103067","volume":"18","author":"H-D Zhang","year":"2024","unstructured":"Zhang H-D, Ding L, Liu K, Mi L-J, Zhang A-K, Yu F-Y, et al. Semaglutide for the prevention of atrial fibrillation: a systematic review and meta-analysis. Diabetes Metab Syndr: Clin Res Rev. 2024;18:103067.","journal-title":"Diabetes Metab Syndr: Clin Res Rev"},{"key":"707_CR48","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/archinternmed.2009.266","volume":"169","author":"GD Foster","year":"2009","unstructured":"Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the sleep AHEAD study. Arch Intern Med. 2009;169:1619\u201326.","journal-title":"Arch Intern Med"},{"key":"707_CR49","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1164\/rccm.200805-669OC","volume":"179","author":"HPI Tuomilehto","year":"2009","unstructured":"Tuomilehto HPI, Sepp\u00e4 JM, Partinen MM, Peltonen M, Gylling H, Tuomilehto JOI, et al. Lifestyle intervention with weight reduction. Am J Respir Crit Care Med. 2009;179:320\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"707_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.sleep.2024.06.014","volume":"121","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Heilmann CR, Banerjee KK, Dunn JP, Bunck MC, Bednarik J. Weight reduction and the impact on apnea-hypopnea index: a systematic meta-analysis. Sleep Med. 2024;121:26\u201331.","journal-title":"Sleep Med"},{"key":"707_CR51","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1164\/rccm.201905-1071ST","volume":"200","author":"B Mokhlesi","year":"2019","unstructured":"Mokhlesi B, Masa JF, Brozek JL, Gurubhagavatula I, Murphy PB, Piper AJ, et al. Evaluation and management of obesity hypoventilation syndrome. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2019;200:e6-24.","journal-title":"Am J Respir Crit Care Med."},{"key":"707_CR52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2869.2012.01030.x","volume":"22","author":"I Idris","year":"2013","unstructured":"Idris I, Abdulla H, Tilbrook S, Dean R, Ali N. Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea. J Sleep Res. 2013;22:70\u20135.","journal-title":"J Sleep Res"},{"key":"707_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12902-015-0074-6","volume":"15","author":"F Gomez-Peralta","year":"2015","unstructured":"Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, et al. An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes. BMC Endocr Disord. 2015;15:78.","journal-title":"BMC Endocr Disord"},{"key":"707_CR54","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201807-1326ST","volume":"198","author":"DW Hudgel","year":"2018","unstructured":"Hudgel DW, Patel SR, Ahasic AM, Bartlett SJ, Bessesen DH, Coaker MA, et al. The role of weight management in the treatment of adult obstructive sleep apnea. an official american thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e70-87.","journal-title":"Am J Respir Crit Care Med."},{"key":"707_CR55","unstructured":"FDA. FDA approves first medication for obstructive sleep apnea [Internet]. 2024 [cited 2025 Oct 7]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea"},{"key":"707_CR56","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Dongen CV, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.","journal-title":"Hepatology"},{"key":"707_CR57","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis. JAMA. 2020;323:1175\u201383.","journal-title":"JAMA"},{"key":"707_CR58","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865\u201373.","journal-title":"Hepatology"},{"key":"707_CR59","doi-asserted-by":"publisher","first-page":"c912","DOI":"10.1136\/bmj.c912","volume":"340","author":"B Liu","year":"2010","unstructured":"Liu B, Balkwill A, Reeves G, Beral V, Collaborators MWS. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010;340:c912.","journal-title":"BMJ"},{"key":"707_CR60","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1111\/apt.17848","volume":"59","author":"A Giannakogeorgou","year":"2024","unstructured":"Giannakogeorgou A, Roden M. Role of lifestyle and glucagon\u2010like peptide\u20101 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases. Aliment Pharmacol Ther. 2024;59:S52-75.","journal-title":"Aliment Pharmacol Ther"},{"key":"707_CR61","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"(EASL) EA for the S of the L, Tacke F, Horn P, Wong V-S, Ratziu V, Bugianesi E, et al. EASL\u2013EASD\u2013EASO Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542.","journal-title":"J Hepatol"},{"key":"707_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","volume":"56","author":"C Thoma","year":"2012","unstructured":"Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255\u201366.","journal-title":"J Hepatol"},{"key":"707_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121\u20139.","journal-title":"Hepatology"},{"key":"707_CR64","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","volume":"60","author":"LM Glass","year":"2015","unstructured":"Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, et al. Total body weight loss of \u226510 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024\u201330. Accessed 22 Oct 2025.","journal-title":"Dig Dis Sci"},{"key":"707_CR65","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/oby.23793","volume":"31","author":"DA Koutoukidis","year":"2023","unstructured":"Koutoukidis DA, Mozes FE, Jebb SA, Tomlinson JW, Pavlides M, Saffioti F, et al. A low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis. Obesity. 2023;31:1767\u201378.","journal-title":"Obesity"},{"key":"707_CR66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-378.e5.","journal-title":"Gastroenterology"},{"key":"707_CR67","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.cgh.2021.03.017","volume":"20","author":"P Jirapinyo","year":"2022","unstructured":"Jirapinyo P, McCarty TR, Dolan RD, Shah R, Thompson CC. Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:511-524.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"707_CR68","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1007\/s11695-022-06011-1","volume":"32","author":"H Zhou","year":"2022","unstructured":"Zhou H, Luo P, Li P, Wang G, Yi X, Fu Z, et al. Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis. Obes Surg. 2022;32:1872\u201383. Accessed 22 Oct 2025.","journal-title":"Obes Surg."},{"key":"707_CR69","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji L-C, Gnemmi V, Baud G, Verkindt H, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159:1290-1301.e5.","journal-title":"Gastroenterology"},{"key":"707_CR70","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","volume":"79","author":"M Romero-G\u00f3mez","year":"2023","unstructured":"Romero-G\u00f3mez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023;79:888\u201397.","journal-title":"J Hepatol"},{"key":"707_CR71","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.3390\/nu14214673","volume":"14","author":"S Volpe","year":"2022","unstructured":"Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D, et al. Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study. Nutrients. 2022;14:4673.","journal-title":"Nutrients"},{"key":"707_CR72","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol. 2022;77:607\u201318.","journal-title":"J Hepatol"},{"key":"707_CR73","doi-asserted-by":"publisher","first-page":"e13037","DOI":"10.1002\/jgh3.13037","volume":"8","author":"P Shah","year":"2024","unstructured":"Shah P, White M, Sievert A, Conway A, Kneepkens A, Sayuk G, et al. Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective study. JGH Open. 2024;8:e13037.","journal-title":"JGH Open"},{"key":"707_CR74","doi-asserted-by":"crossref","unstructured":"Carretero-G\u00f3mez J, Carrasco-S\u00e1nchez FJ, Fern\u00e1ndez-Rodr\u00edguez JM, Casado-Escribano P, Miramontes-Gonz\u00e1lez JP, Segu\u00ed-Ripoll JM, et al. Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity. 2023;223:134\u201343. Available from: https:\/\/www.revclinesp.es\/en-effect-semaglutide-on-fatty-liver-articulo-S2254887422001047","DOI":"10.1016\/j.rceng.2022.12.001"},{"key":"707_CR75","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2020;384:1113\u201324. Accessed 22 Oct 2025.","journal-title":"N Engl J Med"},{"key":"707_CR76","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"707_CR77","unstructured":"FDA. FDA approves treatment for serious liver disease known as \u2018MASH\u2019 [Internet]. [cited 2025 Oct 7]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash"},{"key":"707_CR78","doi-asserted-by":"publisher","first-page":"r1788","DOI":"10.1136\/bmj.r1788","volume":"390","author":"K Bowie","year":"2025","unstructured":"Bowie K. Semaglutide: FDA approves weight loss jab to treat severe liver disease. BMJ. 2025;390:r1788.","journal-title":"BMJ"},{"key":"707_CR79","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Land\u00f3 LF, Bray R, Brouwers B, Rodr\u00edguez \u00c1. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10:393\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"707_CR80","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/dom.15566","volume":"26","author":"B Cariou","year":"2024","unstructured":"Cariou B, Linge J, Neeland IJ, Leinhard OD, Petersson M, Land\u00f3 LF, et al. Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes. Diabetes, Obes Metab. 2024;26:2446\u201355.","journal-title":"Diabetes, Obes Metab"},{"key":"707_CR81","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43:1352\u20135.","journal-title":"Diabetes Care"},{"key":"707_CR82","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299\u2013310.","journal-title":"N Engl J Med"},{"key":"707_CR83","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311\u20139.","journal-title":"N Engl J Med"},{"key":"707_CR84","unstructured":"Kerr M. Chronic kidney disease in England, The Human and financial Cost [Internet]. 2012 Oct. Available from: www.england.nhs.uk\/improvement-hub\/wp-content\/uploads\/sites\/44\/2017\/11\/Chronic-Kidney-Disease-in-England-The-Human-and-Financial-Cost.pdf"},{"key":"707_CR85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","volume":"144","author":"C Hsu","year":"2006","unstructured":"Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21\u20138.","journal-title":"Ann Intern Med"},{"key":"707_CR86","first-page":"k5301","volume":"364","author":"AR Chang","year":"2018","unstructured":"Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2018;364:k5301.","journal-title":"BMJ"},{"key":"707_CR87","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000513664","volume":"52","author":"A D\u00edaz-L\u00f3pez","year":"2021","unstructured":"D\u00edaz-L\u00f3pez A, Becerra-Tom\u00e1s N, Ruiz V, Toledo E, Babio N, Corella D, et al. Effect of an intensive weight-loss lifestyle intervention on kidney function: a randomized controlled trial. Am J Nephrol. 2021;52:45\u201358.","journal-title":"Am J Nephrol"},{"key":"707_CR88","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","volume":"2","author":"Group TLAR","year":"2014","unstructured":"Group TLAR. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2:801\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"707_CR89","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2337\/dc12-1846","volume":"36","author":"A Tirosh","year":"2013","unstructured":"Tirosh A, Golan R, Harman-Boehm I, Henkin Y, Schwarzfuchs D, Rudich A, et al. Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care. 2013;36:2225\u201332.","journal-title":"Diabetes Care"},{"key":"707_CR90","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jamasurg.2020.0829","volume":"155","author":"KH Sheetz","year":"2020","unstructured":"Sheetz KH, Gerhardinger L, Dimick JB, Waits SA. Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease. JAMA Surg. 2020;155:581\u20138.","journal-title":"JAMA Surg"},{"key":"707_CR91","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40620-020-00738-9","volume":"33","author":"CM Mosterd","year":"2020","unstructured":"Mosterd CM, Bjornstad P, Raalte DHvan. Nephroprotective effects of GLP-1 receptor agonists: where do we stand? J Nephrol. 2020;33:965\u201375.","journal-title":"J Nephrol"},{"key":"707_CR92","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","volume":"31","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM, Gorriz JL, Soler MJ, Guldris SC, Cruzado JM, Puchades MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025;31:278\u201385.","journal-title":"Nat Med"},{"key":"707_CR93","doi-asserted-by":"crossref","unstructured":"Group KDIGO (KDIGO) DW, Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, et al. KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102:S1\u2013127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"707_CR94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-024-00511-3","volume":"10","author":"E Stener-Victorin","year":"2024","unstructured":"Stener-Victorin E, Teede H, Norman RJ, Legro R, Goodarzi MO, Dokras A, et al. Polycystic ovary syndrome. Nat Rev Dis Prim. 2024;10:27.","journal-title":"Nat Rev Dis Prim"},{"key":"707_CR95","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(24)00538-5","volume":"403","author":"SNS Samarasinghe","year":"2024","unstructured":"Samarasinghe SNS, Leca B, Alabdulkader S, Dimitriadis GK, Davasgaium A, Thadani P, et al. Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial. Lancet. 2024;403:2489\u2013503.","journal-title":"Lancet"},{"key":"707_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Bokal EV. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179:1\u201311.","journal-title":"Eur J Endocrinol"},{"key":"707_CR97","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.7326\/M23-3179","volume":"177","author":"J Scragg","year":"2024","unstructured":"Scragg J, Hobson A, Willis L, Taylor KS, Dixon S, Jebb SA. Effect of weight loss interventions on the symptomatic burden and biomarkers of polycystic ovary syndrome. Ann Intern Med. 2024;177:1664\u201374.","journal-title":"Ann Intern Med"},{"key":"707_CR98","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.3390\/jcm12185921","volume":"12","author":"E Carmina","year":"2023","unstructured":"Carmina E, Longo RA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med. 2023;12:5921.","journal-title":"J Clin Med"},{"key":"707_CR99","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12958-025-01447-3","volume":"23","author":"H Chen","year":"2025","unstructured":"Chen H, Lei X, Yang Z, Xu Y, Liu D, Wang C, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight\/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025;23:108.","journal-title":"Reprod Biol Endocrinol"},{"key":"707_CR100","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","volume":"5","author":"JD Steinmetz","year":"2023","unstructured":"Steinmetz JD, Culbreth GT, Haile LM, Rafferty Q, Lo J, et al. Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e508-22.","journal-title":"Lancet Rheumatol."},{"key":"707_CR101","doi-asserted-by":"crossref","unstructured":"Dell\u2019Isola A, Recenti F, Giardulli B, Lawford BJ, Kiadaliri A. Osteoarthritis year in review 2025: Epidemiology and Therapy. Osteoarthr Cartil. 2025;","DOI":"10.1016\/j.joca.2025.08.015"},{"key":"707_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiomech.2019.109477","volume":"98","author":"SP Messier","year":"2020","unstructured":"Messier SP, Beavers DP, Mihalko SL, Miller GD, Lyles MF, Hunter DJ, et al. The effects of intensive dietary weight loss and exercise on gait in overweight and obese adults with knee osteoarthritis. The intensive diet and exercise for arthritis (IDEA) trial. J Biomech. 2020;98:109477.","journal-title":"J Biomech"},{"key":"707_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.762","volume":"10","author":"O Baser","year":"2024","unstructured":"Baser O, Isenman L, Baser S, Samayoa G. Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study. Obes Sci Pr. 2024;10:e762.","journal-title":"Obes Sci Pr"},{"key":"707_CR104","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard-2023-223845","volume":"82","author":"H Zhu","year":"2023","unstructured":"Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H, et al. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis. 2023;82:1218\u201326.","journal-title":"Ann Rheum Dis"},{"key":"707_CR105","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, Hemmingsson JU, Hjelmes\u00e6th J, Morville TH, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391:1573\u201383. Accessed 22 Oct 2025.","journal-title":"N Engl J Med"},{"key":"707_CR106","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3520","volume":"4","author":"F Petrelli","year":"2021","unstructured":"Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, et al. Association of obesity with survival outcomes in patients with cancer. JAMA Netw Open. 2021;4:e213520.","journal-title":"JAMA Netw Open"},{"key":"707_CR107","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejogrb.2023.06.028","volume":"288","author":"SS Mooney","year":"2023","unstructured":"Mooney SS, Sumithran P. Does weight loss in women with obesity induce regression of endometrial hyperplasia? A systematic review. Eur J Obstet Gynecol Reprod Biol. 2023;288:49\u201355.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"707_CR108","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2021.01.029","volume":"161","author":"M Janda","year":"2021","unstructured":"Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, et al. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecol Oncol. 2021;161:143\u201351.","journal-title":"Gynecol Oncol"},{"key":"707_CR109","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/aog.0000000000005297","volume":"142","author":"ACOG","year":"2023","unstructured":"ACOG. Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia. Obstet Gynecol. 2023;142:735\u201344. https:\/\/doi.org\/10.1097\/aog.0000000000005297","journal-title":"Obstet Gynecol"},{"key":"707_CR110","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1158\/1940-6207.CAPR-21-0229","volume":"14","author":"CE Barr","year":"2021","unstructured":"Barr CE, Ryan NAJ, Derbyshire AE, Wan YL, MacKintosh ML, McVey RJ, et al. Weight loss during intrauterine progestin treatment for obesity-associated atypical hyperplasia and early-stage cancer of the endometriumprogestin and weight loss for endometrial neoplasia. Cancer Prev Res. 2021;14:1041\u201350.","journal-title":"Cancer Prev Res"},{"key":"707_CR111","doi-asserted-by":"publisher","first-page":"812346","DOI":"10.3389\/fonc.2022.812346","volume":"12","author":"J Chen","year":"2022","unstructured":"Chen J, Cao D, Yang J, Yu M, Zhou H, Cheng N, et al. Fertility-sparing treatment for endometrial cancer or atypical endometrial hyperplasia patients with obesity. Front Oncol. 2022;12:812346.","journal-title":"Front Oncol"},{"key":"707_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2024.07.008","volume":"190","author":"CJ Riedinger","year":"2024","unstructured":"Riedinger CJ, Sakach J, Maples JM, Fulton J, Chippior J, O\u2019Donnell B, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist. Gynecol Oncol. 2024;190:1\u201310.","journal-title":"Gynecol Oncol"},{"key":"707_CR113","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.ejca.2013.03.015","volume":"49","author":"CM Nagle","year":"2013","unstructured":"Nagle CM, Marquart L, Bain CJ, O\u2019Brien S, Lahmann PH, Quinn M, et al. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer. 2013;49:2717\u201326.","journal-title":"Eur J Cancer"},{"key":"707_CR114","unstructured":"Trial Register: Weight-loss drug for fertility-sparing treatment of atypical hyperplasia and low-grade cancer of the endometrium [Internet]. [cited 2025 Oct 4]. Available from: https:\/\/cdek.pharmacy.purdue.edu\/trial\/NCT06073184\/"},{"key":"707_CR115","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s41030-022-00203-x","volume":"8","author":"AG Kaplan","year":"2022","unstructured":"Kaplan AG, Kim JW. Asthma exacerbations and glucagon-like peptide-1 receptor agonists: a review of the current evidence. Pulm Ther. 2022;8:343\u201358.","journal-title":"Pulm Ther"},{"key":"707_CR116","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jaci.2020.08.011","volume":"146","author":"S Miethe","year":"2020","unstructured":"Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. J Allergy Clin Immunol. 2020;146:685\u201393.","journal-title":"J Allergy Clin Immunol"},{"key":"707_CR117","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaci.2018.02.004","volume":"141","author":"U Peters","year":"2018","unstructured":"Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141:1169\u201379.","journal-title":"J Allergy Clin Immunol"},{"key":"707_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100227","volume":"3","author":"C Stridsman","year":"2024","unstructured":"Stridsman C, Martinsen \u00d8, Selberg S, \u00d6dling M, Konradsen JR. Uncontrolled asthma in school-aged children\u2014a nationwide specialist care study. J Allergy Clin Immunol Glob. 2024;3:100227.","journal-title":"J Allergy Clin Immunol Glob"},{"key":"707_CR119","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00612-2020","volume":"57","author":"CA Thompson","year":"2021","unstructured":"Thompson CA, Eslick SR, Berthon BS, Wood LG. Asthma medication use in obese and healthy weight asthma: systematic review\/meta-analysis. Eur Respir J. 2021;57:2000612.","journal-title":"Eur Respir J"},{"key":"707_CR120","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/thoraxjnl-2019-213880","volume":"75","author":"GP Peralta","year":"2020","unstructured":"Peralta GP, Marcon A, Carsin A-E, Abramson MJ, Accordini S, Amaral AF, et al. Body mass index and weight change are associated with adult lung function trajectories: the prospective ECRHS study. Thorax. 2020;75:313\u201320.","journal-title":"Thorax"},{"key":"707_CR121","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/02770903.2019.1590594","volume":"57","author":"\u00dc \u00d6zbey","year":"2020","unstructured":"\u00d6zbey \u00dc, Balaban S, S\u00f6zener Z\u00c7, U\u00e7ar A, Mungan D, M\u0131s\u0131rl\u0131gil Z. The effects of diet-induced weight loss on asthma control and quality of life in obese adults with asthma: a randomized controlled trial. J Asthma. 2020;57:618\u201326.","journal-title":"J Asthma"},{"key":"707_CR122","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1136\/bmj.320.7238.827","volume":"320","author":"B Stenius-Aarniala","year":"2000","unstructured":"Stenius-Aarniala B, Poussa T, Kvarnstr\u00f6m J, Gr\u00f6nlund E-L, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ. 2000;320:827.","journal-title":"BMJ"},{"key":"707_CR123","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1378\/chest.118.5.1315","volume":"118","author":"K Hakala","year":"2000","unstructured":"Hakala K, Stenius-Aarniala B, Sovija\u00a8rvi A. Effects of weight loss on peak flow variability, airways obstruction, and lung volumes in obese patients with asthma. Chest. 2000;118:1315\u201321.","journal-title":"Chest"},{"key":"707_CR124","doi-asserted-by":"crossref","unstructured":"Ma J, Strub P, Xiao L, Lavori PW, Jr. CAC, Wilson SR, et al. Behavioral weight loss and physical activity intervention in obese adults with asthma. a randomized trial. Ann Am Thorac Soc. 2015;12:1\u201311.","DOI":"10.1513\/AnnalsATS.201406-271OC"},{"key":"707_CR125","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.chest.2023.01.015","volume":"163","author":"V Sharma","year":"2023","unstructured":"Sharma V, Ricketts HC, McCombie L, Brosnahan N, Crawford L, Slaughter L, et al. A total diet replacement weight management program for difficult-to-treat asthma associated with obesity a randomized controlled feasibility trial. Chest. 2023;163:1026\u201337.","journal-title":"Chest"},{"key":"707_CR126","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamainternmed.2024.5982","volume":"185","author":"B Lee","year":"2025","unstructured":"Lee B, Man KKC, Wong E, Tan T, Sheikh A, Bloom CI. Antidiabetic medication and asthma attacks. JAMA Intern Med. 2025;185:16\u201325.","journal-title":"JAMA Intern Med"},{"key":"707_CR127","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/crj.13372","volume":"15","author":"J Wei","year":"2021","unstructured":"Wei J, Yang C, Leng W, Ding L, Zhao G. Use of GLP1RAs and occurrence of respiratory disorders: a meta\u2010analysis of large randomized trials of GLP1RAs. Clin Respir J. 2021;15:847\u201350.","journal-title":"Clin Respir J"},{"key":"707_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109080","volume":"183","author":"A Wang","year":"2022","unstructured":"Wang A, Tang H, Zhang N, Feng X. Association between novel glucose-lowering drugs and risk of asthma: a network meta-analysis of cardiorenal outcome trials. Diabetes Res Clin Pract. 2022;183:109080.","journal-title":"Diabetes Res Clin Pract"},{"key":"707_CR129","first-page":"607","volume":"37","author":"M Zhang","year":"2024","unstructured":"Zhang M, Lin C, Cai X, Jiao R, Bai S, Li Z, et al. The association between GLP-1 receptor-based agonists and the incidence of asthma in patients with type 2 diabetes and\/or obesity: a meta-analysis. Biomed Environ Sci. 2024;37:607\u201316.","journal-title":"Biomed Environ Sci"},{"key":"707_CR130","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0625.2008.00712_1.x","volume":"17","author":"H Kurzen","year":"2008","unstructured":"Kurzen H, Kurokawa I, Jemec GBE, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17:455\u201372.","journal-title":"Exp Dermatol"},{"key":"707_CR131","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/ced\/llad109","volume":"48","author":"K Hussain","year":"2023","unstructured":"Hussain K, Khalil N, Patel NP. Hidradenitis suppurativa should be recognized as a weight-related comorbidity in National Institute for Health and Care guidelines on managing obesity. Clin Exp Dermatol. 2023;48:802\u20133.","journal-title":"Clin Exp Dermatol"},{"key":"707_CR132","doi-asserted-by":"publisher","first-page":"e31810","DOI":"10.1371\/journal.pone.0031810","volume":"7","author":"R Sabat","year":"2012","unstructured":"Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7:e31810.","journal-title":"PLoS One"},{"key":"707_CR133","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2340\/00015555-1800","volume":"94","author":"C Kromann","year":"2014","unstructured":"Kromann C, Ibler K, Kristiansen V, Jemec G. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553\u20137.","journal-title":"Acta Derm Venereol"},{"key":"707_CR134","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jdv.14599","volume":"32","author":"PT Riis","year":"2018","unstructured":"Riis PT, Saunte DM, Benhadou F, del Marmol V, Guillem P, El-Domyati M, et al. Low and high body mass index in hidradenitis suppurativa patients\u2014different subtypes? J Eur Acad Dermatol Venereol. 2018;32:307\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"707_CR135","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaad.2009.02.013","volume":"61","author":"F Canoui-Poitrine","year":"2009","unstructured":"Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61:51\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"707_CR136","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2340\/00015555-3830","volume":"101","author":"C Canard","year":"2021","unstructured":"Canard C, Cives AD, Gaubil-Kaladjian I, Bertin E, Viguier M. Impact of bariatric surgery on hidradenitis suppurativa. Acta Derm-Venereol. 2021;101:653.","journal-title":"Acta Derm-Venereol"},{"key":"707_CR137","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/ced.12269","volume":"39","author":"CL Thomas","year":"2014","unstructured":"Thomas CL, Gordon KD, Mortimer PS. Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention. Clin Exp Dermatol. 2014;39:315\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"707_CR138","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjd.15233","volume":"177","author":"L Jennings","year":"2017","unstructured":"Jennings L, Nestor L, Molloy O, Hughes R, Moriarty B, Kirby B. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177:858\u20139.","journal-title":"Br J Dermatol"},{"key":"707_CR139","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","volume":"162","author":"J Nicolau","year":"2024","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, Pujol A, Masmiquel L, Nadal C. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024;162:118\u201322.","journal-title":"Med Clin (Barc)"},{"key":"707_CR140","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10654-018-0366-z","volume":"33","author":"D Aune","year":"2018","unstructured":"Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose\u2013response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:1163\u201378.","journal-title":"Eur J Epidemiol"},{"key":"707_CR141","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/1203475415586332","volume":"19","author":"P Fleming","year":"2015","unstructured":"Fleming P, Kraft J, Gulliver WP, Lynde C. The relationship of obesity with the severity of psoriasis. J Cutan Med Surg. 2015;19:450\u20136.","journal-title":"J Cutan Med Surg"},{"key":"707_CR142","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/oby.21955","volume":"25","author":"C Maglio","year":"2017","unstructured":"Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish Obese Subjects Study. Obesity. 2017;25:2068\u201373.","journal-title":"Obesity"},{"key":"707_CR143","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/bjd.12735","volume":"170","author":"L Naldi","year":"2014","unstructured":"Naldi L, Conti A, Cazzaniga S, Patrizi A, Pazzaglia M, Lanzoni A, et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol. 2014;170:634\u201342.","journal-title":"Br J Dermatol"},{"key":"707_CR144","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1517\/14712598.2014.900541","volume":"14","author":"N Al-Mutairi","year":"2014","unstructured":"Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther. 2014;14:749\u201356.","journal-title":"Expert Opin Biol Ther"},{"key":"707_CR145","first-page":"1148","volume":"22","author":"S Ku","year":"2024","unstructured":"Ku S, Chang H. Efficacy of glucagon\u2010like peptide\u20101 receptor agonists for psoriasis: an updated systematic review and meta\u2010analysis. JDDG: J Dtsch Dermatol Ges. 2024;22:1148\u201352.","journal-title":"JDDG: J Dtsch Dermatol Ges"},{"key":"707_CR146","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bjd.12886","volume":"171","author":"M Buysschaert","year":"2014","unstructured":"Buysschaert M, Baeck M, Preumont V, Marot L, Hendrickx E, Belle AV, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study. Br J Dermatol. 2014;171:155\u201361.","journal-title":"Br J Dermatol"},{"key":"707_CR147","first-page":"23","volume":"2023","author":"AE Malavazos","year":"2023","unstructured":"Malavazos AE, Meregalli C, Sorrentino F, Vignati A, Dubini C, Scravaglieri V, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol, Diabetes Metab Case Rep. 2023;2023:23\u20130017.","journal-title":"Endocrinol, Diabetes Metab Case Rep"},{"key":"707_CR148","first-page":"21","volume":"2021","author":"G Costanzo","year":"2021","unstructured":"Costanzo G, Curatolo S, Bus\u00e0 B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol, Diabetes Metab Case Rep. 2021;2021:21\u20130007.","journal-title":"Endocrinol, Diabetes Metab Case Rep"},{"key":"707_CR149","first-page":"46","volume":"15","author":"J Petkovi\u0107-Dabi\u0107","year":"2025","unstructured":"Petkovi\u0107-Dabi\u0107 J, Bini\u0107 I, Cari\u0107 B, Bo\u017ei\u0107 L, Umi\u010devi\u0107-\u0160ipka S, Bednar\u010duk N, et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label. Randomized Clin Trial Biomol. 2025;15:46.","journal-title":"Randomized Clin Trial Biomol"},{"key":"707_CR150","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/jmedgenet-2018-105315","volume":"55","author":"L Kleinendorst","year":"2018","unstructured":"Kleinendorst L, Massink MPG, Cooiman MI, Savas M, van der Baan-Slootweg OH, Roelants RJ, et al. Genetic obesity: next-generation sequencing results of 1230 patients with obesity. J M\u00e9d Genet. 2018;55:578. Accessed 22 Oct 2025.","journal-title":"J M\u00e9d Genet"},{"key":"707_CR151","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.soard.2019.10.025","volume":"16","author":"JI Mechanick","year":"2020","unstructured":"Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16:175\u2013247. Accessed 22 Oct 2025.","journal-title":"Surg Obes Relat Dis"},{"key":"707_CR152","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/oby.23385","volume":"30","author":"MG Gantz","year":"2022","unstructured":"Gantz MG, Driscoll DJ, Miller JL, Duis JB, Butler MG, Gourash L, et al. Critical review of bariatric surgical outcomes in patients with Prader-Willi syndrome and other hyperphagic disorders. Obesity. 2022;30:973\u201381.","journal-title":"Obesity"},{"key":"707_CR153","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s11695-021-05869-x","volume":"32","author":"MI Cooiman","year":"2022","unstructured":"Cooiman MI, Alsters SIM, Duquesnoy M, Hazebroek EJ, Meijers-Heijboer HJ, Chahal H, et al. Long-term weight outcome after bariatric surgery in patients with melanocortin-4 receptor gene variants: a case-control study of 105 patients. Obes Surg. 2022;32:837\u201344.","journal-title":"Obes Surg"},{"key":"707_CR154","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1007\/s11695-023-06604-4","volume":"33","author":"F Feris","year":"2023","unstructured":"Feris F, Ghusn W, Campos A, Cifuentes L, la Rosa AD, Sacoto D, et al. The effect of heterozygous gene variants of the leptin-melanocortin pathway on weight loss following sleeve gastrectomy. Obes Surg. 2023;33:2246\u20139.","journal-title":"Obes Surg"},{"key":"707_CR155","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1007\/s11695-022-06122-9","volume":"32","author":"A Campos","year":"2022","unstructured":"Campos A, Cifuentes L, Hashem A, Busebee B, Hurtado-Andrade MD, Ricardo-Silgado ML, et al. Effects of heterozygous variants in the leptin-melanocortin pathway on roux-en-y gastric bypass outcomes: a 15-year case-control study. Obes Surg. 2022;32:2632\u201340.","journal-title":"Obes Surg"},{"key":"707_CR156","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.soard.2021.04.020","volume":"17","author":"C Poitou","year":"2021","unstructured":"Poitou C, Puder L, Dubern B, Krabusch P, Genser L, Wiegand S, et al. Long-term outcomes of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR, and MC4R genes. Surg Obes Relat Dis. 2021;17:1449\u201356.","journal-title":"Surg Obes Relat Dis"},{"key":"707_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.792354","volume":"12","author":"EGF Fojas","year":"2022","unstructured":"Fojas EGF, Radha SK, Ali T, Nadler EP, Lessan N. Weight and glycemic control outcomes of bariatric surgery and pharmacotherapy in patients with melanocortin-4 receptor deficiency. Front Endocrinol. 2022;12:792354.","journal-title":"Front Endocrinol"},{"key":"707_CR158","unstructured":"AztraZeneca website. US FDA approves orphan drug MYALEPTTM (metreleptin for injection) [Internet]. 2014 [cited 2025 Oct 5]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2014\/us-fda-approved-myalept-lepti-deficiency-treatment-25022014.html"},{"key":"707_CR159","unstructured":"NICE. Setmelanotide for treating obesity caused by LEPR or POMC deficiency [Internet]. 2022 Jul. Available from: https:\/\/www.nice.org.uk\/guidance\/hst21"},{"key":"707_CR160","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Setmelanotide: first approval. Drugs. 2021;81:397\u2013403.","journal-title":"Drugs"},{"key":"707_CR161","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cmet.2018.05.008","volume":"28","author":"EW Iepsen","year":"2018","unstructured":"Iepsen EW, Zhang J, Thomsen HS, Hansen EL, Hollensted M, Madsbad S, et al. Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Cell Metab. 2018;28:23-32.e3.","journal-title":"Cell Metab"},{"key":"707_CR162","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12481","volume":"11","author":"MS Welling","year":"2021","unstructured":"Welling MS, de Groot CJ, Kleinendorst L, van der Voorn B, Burgerhart JS, van der Valk ES, et al. Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: a case series. Clin Obes. 2021;11:e12481.","journal-title":"Clin Obes"},{"key":"707_CR163","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/dom.15398","volume":"26","author":"S Ali","year":"2024","unstructured":"Ali S, Baig S, Wanninayake S, da Silva Xavier G, Dawson C, Paisey R, et al. Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alstr\u00f6m syndrome patients. Diabetes, Obes Metab. 2024;26:989\u201396.","journal-title":"Diabetes, Obes Metab."},{"key":"707_CR164","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1038\/s41591-025-03913-2","volume":"31","author":"P Bhatnagar","year":"2025","unstructured":"Bhatnagar P, Ahmad NN, Li X, Coghlan M, Kaplan LM, Farooqi IS. Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency. Nat Med. 2025;31:3294\u20136.","journal-title":"Nat Med"},{"key":"707_CR165","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.ackd.2012.10.009","volume":"20","author":"AN Friedman","year":"2013","unstructured":"Friedman AN. Obesity in patients undergoing dialysis and kidney transplantation. Adv Chronic Kidney Dis. 2013;20:128\u201334.","journal-title":"Adv Chronic Kidney Dis"},{"key":"707_CR166","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1111\/j.1600-6143.2010.03330.x","volume":"10","author":"CP Kovesdy","year":"2010","unstructured":"Kovesdy CP, Czira ME, Rudas A, Ujszaszi A, Rosivall L, Novak M, et al. Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant. 2010;10:2644\u201351.","journal-title":"Am J Transplant"},{"key":"707_CR167","doi-asserted-by":"publisher","first-page":"c209","DOI":"10.1159\/000328070","volume":"118","author":"C Dudley","year":"2011","unstructured":"Dudley C, Harden P. Renal association clinical practice guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract. 2011;118:c209\u201324.","journal-title":"Nephron Clin Pract"},{"key":"707_CR168","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41574-021-00600-3","volume":"18","author":"H Long","year":"2022","unstructured":"Long H, Panda S. Time-restricted feeding and circadian autophagy for long life. Nat Rev Endocrinol. 2022;18:5\u20136.","journal-title":"Nat Rev Endocrinol"},{"key":"707_CR169","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/ckj\/sfac090","volume":"15","author":"M Touzot","year":"2022","unstructured":"Touzot M, Ure\u00f1a-Torres P, Dupuy O. Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope? Clin Kidney J. 2022;15:1782\u20134.","journal-title":"Clin Kidney J"},{"key":"707_CR170","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/nep.14277","volume":"29","author":"R Wallace","year":"2024","unstructured":"Wallace R, Hamblin PS, Tully E, Tran J, Nelson C, Levidiotis V. Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease. Nephrology. 2024;29:371\u20134.","journal-title":"Nephrology"},{"key":"707_CR171","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000527919","volume":"12","author":"JCD la Flor","year":"2022","unstructured":"la Flor JCD, Lorenzo JD, Marschall A, Valga F, V\u00e1zquez TM, C\u00edcero ER. Efficacy and safety of semaglutide, a glucagon-like peptide-1 receptor agonist in real-life: a case series of patients in maintenance incremental hemodialysis. Case Rep Nephrol Dial. 2022;12:238\u201347.","journal-title":"Case Rep Nephrol Dial"},{"key":"707_CR172","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2215\/CJN.0000000750","volume":"20","author":"BJ Orandi","year":"2025","unstructured":"Orandi BJ, Chen Y, Li Y, Charyton D, Lentine KL, Lee BP, et al. GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis. Clin J Am Soc Nephrol. 2025;20:1100\u201310. https:\/\/doi.org\/10.2215\/cjn.0000000750","journal-title":"Clin J Am Soc Nephrol"},{"key":"707_CR173","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diseases12010014","volume":"12","author":"P Krisanapan","year":"2024","unstructured":"Krisanapan P, Sanpawithayakul K, Pattharanitima P, Thongprayoon C, Miao J, Mao MA, et al. Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis. Diseases. 2024;12:14. https:\/\/doi.org\/10.3390\/diseases12010014","journal-title":"Diseases"},{"key":"707_CR174","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/apt.14139","volume":"46","author":"M Barone","year":"2017","unstructured":"Barone M, Viggiani MT, Losurdo G, Principi M, Leandro G, Leo AD. Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity. Aliment Pharmacol Ther. 2017;46:236\u201345.","journal-title":"Aliment Pharmacol Ther"},{"key":"707_CR175","doi-asserted-by":"publisher","first-page":"e021346","DOI":"10.1161\/JAHA.121.021346","volume":"10","author":"F Chouairi","year":"2021","unstructured":"Chouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, et al. Impact of obesity on heart transplantation outcomes. J Am Hear Assoc: Cardiovasc Cerebrovasc Dis. 2021;10:e021346.","journal-title":"J Am Hear Assoc: Cardiovasc Cerebrovasc Dis"},{"key":"707_CR176","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/ijo.2016.20","volume":"40","author":"J Nagendran","year":"2016","unstructured":"Nagendran J, Moore MD, Norris CM, Khani-Hanjani A, Graham MM, Freed DH, et al. The varying effects of obesity and morbid obesity on outcomes following cardiac transplantation. Int J Obes. 2016;40:721\u20134.","journal-title":"Int J Obes"},{"key":"707_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","volume":"35","author":"MR Mehra","year":"2016","unstructured":"Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update. J Hear Lung Transplant. 2016;35:1\u201323.","journal-title":"J Hear Lung Transplant"},{"key":"707_CR178","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstr\u00f8m SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403:1635\u201348.","journal-title":"Lancet"},{"key":"707_CR179","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.transproceed.2016.12.002","volume":"49","author":"SJ Bozso","year":"2017","unstructured":"Bozso SJ, Nagendran Je, Gill RS, Freed DH, Nagendran Ja. Impact of obesity on heart and lung transplantation: does pre-transplant obesity affect outcomes? Transplant Proc. 2017;49:344\u20137.","journal-title":"Transplant Proc"},{"key":"707_CR180","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/tri.12721","volume":"29","author":"S Upala","year":"2016","unstructured":"Upala S, Panichsillapakit T, Wijarnpreecha K, Jaruvongvanich V, Sanguankeo A. Underweight and obesity increase the risk of mortality after lung transplantation: a systematic review and meta-analysis. Transpl Int. 2016;29:285\u201396.","journal-title":"Transpl Int"},{"key":"707_CR181","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.healun.2014.11.018","volume":"34","author":"S Chandrashekaran","year":"2015","unstructured":"Chandrashekaran S, Keller CA, Kremers WK, Peters SG, Hathcock MA, Kennedy CC. Weight loss prior to lung transplantation is associated with improved survival. J Heart Lung Transplant. 2015;34:651\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"707_CR182","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.healun.2018.07.015","volume":"37","author":"ES Clausen","year":"2018","unstructured":"Clausen ES, Frankel C, Palmer SM, Snyder LD, Smith PJ. Pre-transplant weight loss and clinical outcomes after lung transplantation. J Heart Lung Transplant. 2018;37:1443\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"707_CR183","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.2106\/JBJS.K.00820","volume":"94","author":"GMMJ Kerkhoffs","year":"2012","unstructured":"Kerkhoffs GMMJ, Servien E, Dunn W, Dahm D, Bramer JAM, Haverkamp D. The influence of obesity on the complication rate and outcome of total knee arthroplasty: a meta-analysis and systematic literature review. J Bone Joint Surg Am. 2012;94:1839\u201344.","journal-title":"J Bone Joint Surg Am"},{"key":"707_CR184","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12871-015-0096-7","volume":"15","author":"EKM Tjeertes","year":"2015","unstructured":"Tjeertes EKM, Tjeertes EEKM, Hoeks SE, Hoeks SSE, Beks SBJ, Beks SSBJC, et al. Obesity \u2013 a risk factor for postoperative complications in general surgery? BMC Anesthesiol. 2015;15:112.","journal-title":"BMC Anesthesiol"},{"key":"707_CR185","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/BRS.0000000000000232","volume":"39","author":"A Marquez-Lara","year":"2014","unstructured":"Marquez-Lara A, Nandyala SV, Sankaranarayanan S, Noureldin M, Singh K. Body mass index as a predictor of complications and mortality after lumbar spine surgery. Spine (Phila Pa 1976). 2014;39:798\u2013804.","journal-title":"Spine (Phila Pa 1976)"},{"key":"707_CR186","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jvs.2021.10.053","volume":"75","author":"AA Naiem","year":"2022","unstructured":"Naiem AA, Kim AY, Mahmoud I, Gill HL. A systematic review and meta-analysis evaluating the impact of obesity on outcomes of abdominal aortic aneurysm treatment. J Vasc Surg. 2022;75:1450-1455.e3.","journal-title":"J Vasc Surg"},{"key":"707_CR187","doi-asserted-by":"publisher","first-page":"e017689","DOI":"10.1136\/bmjopen-2017-017689","volume":"8","author":"D Pozzobon","year":"2018","unstructured":"Pozzobon D, Ferreira PH, Blyth FM, Machado GC, Ferreira ML. Can obesity and physical activity predict outcomes of elective knee or hip surgery due to osteoarthritis? A meta-analysis of cohort studies. BMJ Open. 2018;8:e017689.","journal-title":"BMJ Open"},{"key":"707_CR188","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.injury.2020.05.006","volume":"51","author":"A Benedick","year":"2020","unstructured":"Benedick A, Audet MA, Vallier HA. The effect of obesity on post-operative complications and functional outcomes after surgical treatment of torsional ankle fracture: a matched cohort study. Injury. 2020;51:1893\u20138.","journal-title":"Injury"},{"key":"707_CR189","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/ans.17138","volume":"91","author":"JR Onggo","year":"2021","unstructured":"Onggo JR, Ang JJM, Onggo JD, de Steiger R, Hau R. Greater risk of all-cause revisions and complications for obese patients in 3 106 381 total knee arthroplasties: a meta-analysis and systematic review. ANZ J Surg. 2021;91:2308\u201321.","journal-title":"ANZ J Surg"},{"key":"707_CR190","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3171\/2020.6.SPINE20592","volume":"34","author":"C Park","year":"2021","unstructured":"Park C, Garcia AN, Cook C, Shaffrey CI, Gottfried ON. Long-term impact of obesity on patient-reported outcomes and patient satisfaction after lumbar spine surgery: an observational study. J Neurosurg Spine. 2021;34:73\u201382.","journal-title":"J Neurosurg Spine"},{"key":"707_CR191","doi-asserted-by":"publisher","first-page":"i5594","DOI":"10.1136\/bmj.i5594","volume":"355","author":"D Shaw","year":"2016","unstructured":"Shaw D. Delaying surgery for obese patients or smokers is a bad idea. BMJ. 2016;355:i5594.","journal-title":"BMJ"},{"key":"707_CR192","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.surg.2023.08.011","volume":"174","author":"T McKechnie","year":"2023","unstructured":"McKechnie T, Lee Y, Hong D, Dionne J, Doumouras A, Parpia S, et al. A history of bariatric surgery before surgery for colorectal cancer may improve short-term postoperative outcomes: Analysis of the national inpatient sample 2015\u20132019. Surgery. 2023;174:1168\u201374.","journal-title":"Surgery"},{"key":"707_CR193","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.6722","volume":"5","author":"MM Dowsey","year":"2022","unstructured":"Dowsey MM, Brown WA, Cochrane A, Burton PR, Liew D, Choong PF. Effect of bariatric surgery on risk of complications after total knee arthroplasty. JAMA Netw Open. 2022;5:e226722.","journal-title":"JAMA Netw Open"},{"key":"707_CR194","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1457496919883812","volume":"110","author":"A Liljens\u00f8e","year":"2019","unstructured":"Liljens\u00f8e A, Laursen JO, Bliddal H, S\u00f8balle K, Mechlenburg I. Weight loss intervention before total knee replacement: a 12-month randomized controlled trial. Scand J Surg. 2019;110:3\u201312.","journal-title":"Scand J Surg"},{"key":"707_CR195","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.arth.2023.08.038","volume":"39","author":"AJ Rechenmacher","year":"2024","unstructured":"Rechenmacher AJ, Yancy WS, Bolognesi MP, Ryan SP, Jiranek WA, Horn ME. Does medically supervised weight loss prior to total knee arthroplasty improve patient-reported pain and physical function? J Arthroplast. 2024;39:350\u20134.","journal-title":"J Arthroplast"},{"key":"707_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s42836-024-00237-3","volume":"6","author":"J Schmerler","year":"2024","unstructured":"Schmerler J, Hussain N, Kurian SJ, Khanuja HS, Oni JK, Hegde V. Preoperative weight loss before total hip arthroplasty negatively impacts postoperative outcomes. Arthroplasty. 2024;6:13.","journal-title":"Arthroplasty"},{"key":"707_CR197","doi-asserted-by":"publisher","first-page":"106778","DOI":"10.1016\/j.ijsu.2022.106778","volume":"104","author":"M Yan","year":"2022","unstructured":"Yan M, Zheng G, Long Z, Pan Q, Wang X, Li Y, et al. Does bariatric surgery really benefit patients before total knee arthroplasty? A systematic review and meta-analysis. Int J Surg. 2022;104:106778.","journal-title":"Int J Surg"},{"key":"707_CR198","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.arth.2018.11.018","volume":"34","author":"S Li","year":"2019","unstructured":"Li S, Luo X, Sun H, Wang K, Zhang K, Sun X. Does prior bariatric surgery improve outcomes following total joint arthroplasty in the morbidly obese? A meta-analysis. J Arthroplasty. 2019;34:577\u201385.","journal-title":"J Arthroplasty"},{"key":"707_CR199","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42836-024-00252-4","volume":"6","author":"LCM Lau","year":"2024","unstructured":"Lau LCM, Chan PK, Lui TWD, Choi SW, Au E, Leung T, et al. Preoperative weight loss interventions before total hip and knee arthroplasty: a systematic review of randomized controlled trials. Arthroplasty. 2024;6:30.","journal-title":"Arthroplasty"},{"key":"707_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105114","volume":"88","author":"K Godziuk","year":"2021","unstructured":"Godziuk K, Prado CM, Beaupre L, Jones CA, Werle JR, Forhan M. A critical review of weight loss recommendations before total knee arthroplasty. Jt Bone Spine. 2021;88:105114.","journal-title":"Jt Bone Spine"},{"key":"707_CR201","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13643-015-0107-2","volume":"4","author":"M Lui","year":"2015","unstructured":"Lui M, Jones CA, Westby MD. Effect of non-surgical, non-pharmacological weight loss interventions in patients who are obese prior to hip and knee arthroplasty surgery: a rapid review. Syst Rev. 2015;4:121.","journal-title":"Syst Rev"},{"key":"707_CR202","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.arth.2021.06.021","volume":"36","author":"MW Seward","year":"2021","unstructured":"Seward MW, Briggs LG, Bain PA, Chen AF. Preoperative nonsurgical weight loss interventions before total hip and knee arthroplasty: a systematic review. J Arthroplasty. 2021;36:3796-3806.e8.","journal-title":"J Arthroplasty"},{"key":"707_CR203","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s11695-016-2421-8","volume":"27","author":"H Hussan","year":"2017","unstructured":"Hussan H, Stanich PP, Gray DM 2nd, Krishna SG, Porter K, Conwell DL, et al. Prior bariatric surgery is linked to improved colorectal cancer surgery outcomes and costs: a propensity-matched analysis. Obes Surg. 2017;27:1047\u201355.","journal-title":"Obes Surg"},{"key":"707_CR204","doi-asserted-by":"publisher","first-page":"108743","DOI":"10.1016\/j.ejso.2024.108743","volume":"50","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Bellafronte NT, Najafitirehshabankareh G, Jimenez MH, Jaeger-McEnroe E, Plourde H, et al. A scoping review of preoperative weight loss interventions on postoperative outcomes for patients with gastrointestinal cancer. Eur J Surg Oncol. 2024;50:108743.","journal-title":"Eur J Surg Oncol"},{"key":"707_CR205","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1200\/JCO.22.00687","volume":"40","author":"JA Ligibel","year":"2022","unstructured":"Ligibel JA, Bohlke K, May AM, Clinton SK, Demark-Wahnefried W, Gilchrist SC, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022;40:2491\u2013507.","journal-title":"J Clin Oncol"},{"key":"707_CR206","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1007\/s00464-024-11016-1","volume":"38","author":"N Chowdhury","year":"2024","unstructured":"Chowdhury N, Hasnan S, Ullah S, Thompson SK. Low-calorie diets are effective for weight loss in patients undergoing benign upper gastrointestinal surgery: a systematic review and meta-analysis. Surg Endosc. 2024;38:4171\u201385.","journal-title":"Surg Endosc"},{"key":"707_CR207","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11695-020-05070-6","volume":"31","author":"MM Romeijn","year":"2021","unstructured":"Romeijn MM, Kolen AM, Holthuijsen DDB, Janssen L, Schep G, Leclercq WKG, et al. Effectiveness of a low-calorie diet for liver volume reduction prior to bariatric surgery: a systematic review. Obes Surg. 2021;31:350\u20136.","journal-title":"Obes Surg"},{"key":"707_CR208","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.soard.2022.10.027","volume":"19","author":"S Abbott","year":"2023","unstructured":"Abbott S, Price C, Pournaras DJ, Coulman K, Group of the BO and MSSBR. Variation and outcomes of liver-reducing dietary regimens before bariatric surgery: a national retrospective cohort study. Surg Obes Relat Dis. 2023;19:102\u20138.","journal-title":"Surg Obes Relat Dis"},{"key":"707_CR209","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/ijo.2012.60","volume":"36","author":"CN Ochner","year":"2012","unstructured":"Ochner CN, Dambkowski CL, Yeomans BL, Teixeira J, Pi-Sunyer FX. Pre-bariatric surgery weight loss requirements and the effect of preoperative weight loss on postoperative outcome. Int J Obes. 2012;36:1380\u20137. Accessed 22 Oct 2025.","journal-title":"Int J Obes"},{"key":"707_CR210","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11605-021-05055-5","volume":"26","author":"JS Samaan","year":"2022","unstructured":"Samaan JS, Zhao J, Qian E, Hernandez A, Toubat O, Alicuben ET, et al. Preoperative weight loss as a predictor of bariatric surgery postoperative weight loss and complications. J Gastrointest Surg. 2022;26:86\u201393.","journal-title":"J Gastrointest Surg"},{"key":"707_CR211","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s11695-018-03660-z","volume":"29","author":"T Stefura","year":"2019","unstructured":"Stefura T, Dro\u015b J, Kacprzyk A, Wierdak M, Proczko-Stepaniak M, Szyma\u0144ski M, et al. Influence of preoperative weight loss on outcomes of bariatric surgery for patients under the enhanced recovery after surgery protocol. Obes Surg. 2019;29:1134\u201341.","journal-title":"Obes Surg"},{"key":"707_CR212","doi-asserted-by":"publisher","first-page":"e204803","DOI":"10.1001\/jamanetworkopen.2020.4803","volume":"3","author":"Y Sun","year":"2020","unstructured":"Sun Y, Liu B, Smith JK, Correia MLG, Jones DL, Zhu Z, et al. Association of preoperative body weight and weight loss with risk of death after bariatric surgery. JAMA Netw Open. 2020;3:e204803.","journal-title":"JAMA Netw Open"},{"key":"707_CR213","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.soard.2011.08.011","volume":"7","author":"S Cassie","year":"2011","unstructured":"Cassie S, Menezes C, Birch DW, Shi X, Karmali S. Effect of preoperative weight loss in bariatric surgical patients: a systematic review. Surg Obes Relat Dis. 2011;7:760\u20137.","journal-title":"Surg Obes Relat Dis"},{"key":"707_CR214","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.soard.2016.04.019","volume":"12","author":"JJ Kim","year":"2016","unstructured":"Kim JJ, Rogers AM, Ballem N, Schirmer B. ASMBS updated position statement on insurance mandated preoperative weight loss requirements. Surg Obes Relat Dis. 2016;12:955\u20139.","journal-title":"Surg Obes Relat Dis"},{"key":"707_CR215","unstructured":"ASMBS. Pre-operative use Of GLP-1s may reduce complications after metabolic and bariatric surgery in patients with extreme obesity [Internet]. 2024 [cited 2025 Oct 5]. Available from: https:\/\/asmbs.org\/news_releases\/pre-operative-use-of-glp-1s-may-reduce-complications-after-metabolic-and-bariatric-surgery-in-patients-with-extreme-obesity\/"},{"key":"707_CR216","doi-asserted-by":"publisher","first-page":"7152","DOI":"10.1007\/s00464-024-11231-w","volume":"38","author":"G Martines","year":"2024","unstructured":"Martines G, Giove C, Carlucci B, Dezi A, Ranieri C, Rotelli MT, et al. Effect of preoperative liraglutide 3.0 mg on incidence of intraoperative adhesions in laparoscopic sleeve gastrectomy. Surg Endosc. 2024;38:7152\u20137.","journal-title":"Surg Endosc."},{"key":"707_CR217","doi-asserted-by":"publisher","DOI":"10.1002\/anr3.12278","volume":"12","author":"SA Avraham","year":"2024","unstructured":"Avraham SA, Hossein J, Somri F, Hawash N, Hochman O. Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss. Anaesth Rep. 2024;12:e12278.","journal-title":"Anaesth Rep"},{"key":"707_CR218","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.bja.2024.01.001","volume":"132","author":"ML van Zuylen","year":"2024","unstructured":"van Zuylen ML, Siegelaar SE, Plummer MP, Deane AM, Hermanides J, Hulst AH. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration. Br J Anaesth. 2024;132:644\u20138.","journal-title":"Br J Anaesth"},{"key":"707_CR219","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bja.2025.04.001","volume":"135","author":"AD Oprea","year":"2025","unstructured":"Oprea AD, Ostapenko LJ, Sweitzer B, Selzer A, Irizarry-Alvarado JM, Andrade MDH, et al. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: society for perioperative assessment and quality improvement (SPAQI) multidisciplinary consensus statement. Br J Anaesth. 2025;135:48\u201378.","journal-title":"Br J Anaesth"},{"key":"707_CR220","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/anae.16541","volume":"80","author":"K El-Boghdadly","year":"2025","unstructured":"El-Boghdadly K, Dhesi J, Fabb P, Levy N, Lobo DN, McKechnie A, et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement. Anaesthesia. 2025;80:412\u201324.","journal-title":"Anaesthesia"},{"key":"707_CR221","doi-asserted-by":"publisher","first-page":"e14895","DOI":"10.1111\/cns.14895","volume":"30","author":"C Zhou","year":"2024","unstructured":"Zhou C, Zhou Y, Liu L, Jiang H, Wei H, Zhou C, et al. Progress and recognition of idiopathic intracranial hypertension: a narrative review. CNS Neurosci Ther. 2024;30:e14895.","journal-title":"CNS Neurosci Ther"},{"key":"707_CR222","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1001\/jamaneurol.2019.1812","volume":"76","author":"NJ Adderley","year":"2019","unstructured":"Adderley NJ, Subramanian A, Nirantharakumar K, Yiangou A, Gokhale KM, Mollan SP, et al. Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol. 2019;76:1088\u201398.","journal-title":"JAMA Neurol"},{"key":"707_CR223","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ajo.2006.12.040","volume":"143","author":"AB Daniels","year":"2007","unstructured":"Daniels AB, Liu GT, Volpe NJ, Galetta SL, Moster ML, Newman NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. 2007;143:635\u201341.","journal-title":"Am J Ophthalmol"},{"key":"707_CR224","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.1097\/WNO.0000000000001107","volume":"41","author":"JL Ang","year":"2021","unstructured":"Ang JL, Teo KZ, Fraser CL. Weight loss in idiopathic intracranial hypertension: a retrospective review of outcomes in the clinical setting. J Neuro-Ophthalmol. 2021;41:e458-63.","journal-title":"J Neuro-Ophthalmol"},{"key":"707_CR225","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/jnnp-2017-317440","volume":"89","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol, Neurosurg Psychiatry. 2018;89:1088\u2013100.","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"707_CR226","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1212\/WNL.0b013e3182190f51","volume":"76","author":"MW Ko","year":"2011","unstructured":"Ko MW, Chang SC, Ridha MA, Ney JJ, Ali TF, Friedman DI, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology. 2011;76:1564\u20137.","journal-title":"Neurology"},{"key":"707_CR227","doi-asserted-by":"publisher","first-page":"c2701","DOI":"10.1136\/bmj.c2701","volume":"341","author":"AJ Sinclair","year":"2010","unstructured":"Sinclair AJ, Burdon MA, Nightingale PG, Ball AK, Good P, Matthews TD, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;341:c2701.","journal-title":"BMJ"},{"key":"707_CR228","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamaneurol.2021.0659","volume":"78","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Mitchell JL, Ottridge RS, Aguiar M, Yiangou A, Alimajstorovic Z, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension. JAMA Neurol. 2021;78:678\u201386.","journal-title":"JAMA Neurol"},{"key":"707_CR229","doi-asserted-by":"publisher","first-page":"e1090","DOI":"10.1212\/WNL.0000000000200839","volume":"99","author":"SP Mollan","year":"2022","unstructured":"Mollan SP, Mitchell JL, Yiangou A, Ottridge RS, Alimajstorovic Z, Cartwright DM, et al. Association of amount of weight lost after bariatric surgery with intracranial pressure in women with idiopathic intracranial hypertension. Neurology. 2022;99:e1090\u20139.","journal-title":"Neurology"},{"key":"707_CR230","doi-asserted-by":"publisher","first-page":"e2138","DOI":"10.1212\/WNL.0000000000207866","volume":"101","author":"S Abbott","year":"2023","unstructured":"Abbott S, Chan F, Tahrani AA, Wong SH, Campbell FEJ, Parmar C, et al. Weight management interventions for adults with idiopathic intracranial hypertension. Neurology. 2023;101:e2138\u201350.","journal-title":"Neurology"},{"key":"707_CR231","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/brain\/awad003","volume":"146","author":"JL Mitchell","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146:1821\u201330.","journal-title":"Brain"},{"key":"707_CR232","doi-asserted-by":"publisher","first-page":"6616693","DOI":"10.1155\/2021\/6616693","volume":"2021","author":"X Lyu","year":"2021","unstructured":"Lyu X, Lyu T, Wang X, Zhu H, Pan H, Wang L, et al. The Antiobesity effect of GLP-1 receptor agonists alone or in combination with metformin in overweight \/obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Int J Endocrinol. 2021;2021:6616693.","journal-title":"Int J Endocrinol"},{"key":"707_CR233","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081989","volume":"10","author":"M Jensterle","year":"2022","unstructured":"Jensterle M, Herman R, Jane\u017e A. Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives. Biomedicines. 2022;10:1989.","journal-title":"Biomedicines"},{"key":"707_CR234","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"707_CR235","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613\u201326.","journal-title":"Lancet"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00707-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00707-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00707-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:38:46Z","timestamp":1775104726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00707-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":235,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00707-6","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Conflicts of interest\/Competing interests Funding: JM has received research funding from the NIHR and the Society for Endocrinology. JM has received institutional funding form NovoNordisk and Rhythm Pharmaceuticals. JS is supported by the NIHR Oxford Biomedical Research Centre (NIHR203311) and is an investigator in a trial funded by the Novo Nordisk Foundation (NNF22SA0080921). IS has received research grants or Speaker fees from: Eli Lilly, Novo Nordisk, Abbott, Boehringer, Sanofi. PSG has received speaker & course director fees from Novo Nordisk, advisory\/speaker fees from Eli Lilly, and research support from Recordari. BM has received educational and\/or advisory fees Lilly, Novonordisk, Boheringer ingelheim, Astra Zeneca. BM has received a research grant from Novo Nordisk. CA has received reimbursement for attending conferences from Novo Nordisk. Financial interests: TT declares she is a former shareholder in, and consultant for Zihipp Ltd., as well as advisory board consultancies for Amylyx Inc. Non-financial interests: JM has a voluntary role with the Asociation for the Study of Obesity (ASO) as sponsorship lead. BM is a shareholder of Reset Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}},{"value":"This article does not contain any studies with\u00a0human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"29"}}